01.07.2022 • NewsItalmatchchemicalsOil & Gas

Italmatch Boosts Oil & Gas Chemicals with Aubin Buy

Italian multinational specialty chemicals company Italmatch has acquired Aubin Group from investment firm BGF, its owner since October 2013. Financial terms of the transaction were not disclosed.

© PICHITBO/Shutterstock
© PICHITBO/Shutterstock

Headquartered in Ellon, Aberdeenshire in Scotland, and with offices and warehouses across the UK and Middle East, Aubin develops and supplies chemicals for the oil & gas, and renewable energy sectors.

Italmatch said the deal boosts its position in key strategic markets such as the Middle East, the US and the North Sea.

“Aubin is a key player in well services and technologies (including cementing) that complement Italmatch’s portfolio. The company is also positioned to be at the forefront of the energy transition through its portfolio of innovative technology tailored to solving unique challenges,” said Scott Miller, Italmatch’s oil & gas sales & marketing director and recently appointed CEO of Aubin Group. “

The Scottish group’s portfolio includes projects in offshore wind developments as well as a disruptive solution to plug disused oil wells even in the harshest conditions, guaranteeing their long-term integrity and reducing their environmental impact.

Author: Elaine Burridge, Freelance Journalist

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read